Navigation
Hair Loss News Archives
April 2006
Mylan Cleared to Market Proscar Generic
Mylan Receives FDA Clearance for Generic Version of Merck's Proscar Prostate-Cancer Drug
Generic-pharmaceutical company Mylan Laboratories Inc. said Tuesday the U.S. Food and Drug Administration granted tentative approval for the company's generic version of Merck & Co.'s Proscar.
Mylan applied to the FDA to market finasteride tablets as a generic version of Proscar, which treats prostate cancer and male-pattern baldness.
Mylan cited IMS Health that measured Proscar's 2005 U.S. sales at $390 million.
Mylan Laboratories shares rose a penny to $22.13 while Merck shares rose 25 cents to $34.05 in morning trading on the New York Stock Exchange.